(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of -34.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Arvinas's revenue in 2025 is $372,800,000.On average, 8 Wall Street analysts forecast ARVN's revenue for 2025 to be $18,439,709,995, with the lowest ARVN revenue forecast at $9,669,097,262, and the highest ARVN revenue forecast at $22,465,784,070. On average, 8 Wall Street analysts forecast ARVN's revenue for 2026 to be $10,328,387,265, with the lowest ARVN revenue forecast at $4,992,396,460, and the highest ARVN revenue forecast at $20,263,256,220.
In 2027, ARVN is forecast to generate $9,040,422,396 in revenue, with the lowest revenue forecast at $4,641,460,356 and the highest revenue forecast at $14,442,709,288.